Significantly more patients who received ocriplasmin experienced resolution of vitreomacular adhesions and closure of macular holes than patients who received placebo, according to results from a study published in the August 16 issue of the New England Journal of Medicine. Despite the statistical significance of the results, only a small percentage of patients stand to benefit. Just 13.4% of the patients receiving ocriplasmin achieved nonsurgical resolution of vitreomacular adhesion at day 28.
To see more details visit,www.medscape.com
